Cyprus Monitoring Centre for Drugs and Drug Addiction

The Cyprus Monitoring Centre for Drugs and Drug Addiction (CMCDDA) operates within the framework of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The Cyprus focal point is a member of the Reitox network, which currently includes each of the 27 EU Member States plus Croatia, Turkey, Norway and the European Commission.

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993 and is based in Lisbon. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. It currently offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research. For more information about the EMCDDA please follow the link [http://www.emcdda.europa.eu/about]

The National Focal Point was established in 2003 and operates within the organizational framework of the Cyprus Anti-drugs Council.

Scientific Committee of the CMCDDA

The Scientific Committee provides scientific support and supervision, and in effect improves the effectiveness of the work carried out by the CMCDDA.

More specifically:

  • It examines, evaluates and edits reports, including various other publications and information material produced by CMCDDA.
  • It is informed about research results and shares opinions as regards to the findings from the research conducted by the CMCDDA.
  • It provides scientific supervision for the work of the CMCDDA, as regards to the goals and methodology of studies, including the processing and presentation of results so as to provide solid and reliable information for the Board of Directors of the CAC, which in effect can be used for the development of evidence based actions and programmes.
  • It submits recommendations for changes in existing research protocols and other research to the Board of Directors, aiming to improve the quantity as well as quality of the information produced.
  • It studies the situation of the drug using phenomenon, as reported by the CMCDDA’s estimates and submits recommendations to the CAC for possible areas or population groups that may present a need for further investigation.
  • It develops a communications network, where representatives from different academic institutions and research organisations that carry out research projects nationally can participate, thereby enhancing synergies and cooperation.

The CMCDDA’s Scientific Committee consists of the following members:

  • Dr. Chrysanthos Georgiou- President of the Board of Directors or Dr Spyros Stylianou (Member of the CAC)
  • Dr Lambros Samartzis
  • Dr. Michael Michaelides
  • Dr. Spyros Spyrou
  • Mr. Loris Neokleous